Abstract
Chemotherapy-induced thrombocytopenia causes nearly two-thirds of cases of hrombocytopenia in the cancer setting In patients receiving chemotherapy thrombocytopenia leads to dose reductions in 15% of treatment cycles and chemotherapy delays in 6% of cycles In this issue of ONCOLOGY Dr Kuter insightfully summarizes the differential diagnosis and management of thrombocytopenia in cancer patients[1] Chemotherapy-induced thrombocytopenia causes nearly two-thirds of cases of hrombocytopenia in the cancer setting[2] In patients receiving chemotherapy thrombocytopenia leads to dose reductions in 15% of treatment cycles and chemotherapy delays in 6% of cycles
Original language | English (US) |
---|---|
Journal | Oncology (United States) |
Volume | 29 |
Issue number | 4 |
State | Published - 2015 |
ASJC Scopus subject areas
- Oncology
- Cancer Research